Brief: Mira Pharmaceuticals Inc - Announces Positive Study Results For Ketamir-2
16/04/2025 12:35
April 16 (Reuters) - Mira Pharmaceuticals Inc MIRA.O: MIRA PHARMACEUTICALS INC - ANNOUNCES POSITIVE STUDY RESULTS FOR KETAMIR-2 - SEC FILING MIRA PHARMACEUTICALS INC - KETAMIR-2 SHOWS SIGNIFICANT REDUCTION IN NEUROPATHIC PAIN SYMPTOMS - SEC FILING MIRA PHARMACEUTICALS INC - TO INITIATE PHASE IIA TRIAL IN DIABETIC NEUROPATHY PATIENTS BY END OF 2025 Further company coverage: MIRA.O ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Mira Pharmaceuticals
See all newsBrief: Mira Pharmaceuticals - Alan Weichselbaum To Step Down As CFO Effective June 6, 2026 - SEC Filing
Brief: MIRA Pharmaceuticals Secures Worldwide Exclusive Rights To MIRA-55 And SKNY-1 - SEC Filing
Brief: Mira Pharmaceuticals Enters Into Amendment No 1 To Exclusive License Agreement With Miralogx
Brief: Mira Pharmaceuticals Inc - Completes Phase 1 Dosing Of Ketamir-2 - SEC Filing
Brief: Mira Pharmaceuticals Inc - Initiates Phase 1 Study Of Ketamir-2 - SEC Filing